Research Paper Volume 16, Issue 1 pp 550—567
Effectiveness and safety of afatinib, gefitinib, and erlotinib for treatment-naïve elderly patients with epidermal growth factor receptor-mutated advanced non-small-cell lung cancer: a multi-institute retrospective study
Figure 1. Forest plot of progression-free survival (PFS) and overall survival (OS) of elderly patients (age ≥65 years) treated with afatinib, gefitinib, or erlotinib. Abbreviations: HR, hazard ratio; CI, confidence interval.